scholarly journals Intradermal Recombinant Hepatitis B Vaccine for Healthcare Workers Who Fail to Respond to Intramuscular Vaccine

2002 ◽  
Vol 23 (2) ◽  
pp. 87-90 ◽  
Author(s):  
E. Geoffrey Playford ◽  
Patrick G. Hogan ◽  
Amolak S. Bansal ◽  
Kareena Harrison ◽  
David Drummond ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Healthcare Workers ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Antibody Concentration ◽  
Recombinant Hepatitis ◽  
Tertiary Referral Hospital ◽  
District Health ◽  
Humoral Immune

Objective:To study the humoral immune responses, safety, and tolerability of intradermal recombinant hepatitis B vaccination in healthcare workers (HCWs) nonresponsive to previous repeated intramuscular vaccination.Design:An open, prospective, before–after trial.Setting:A tertiary referral hospital and surrounding district health service in Queensland, Australia.Participants:Hospital and community HCWs nonresponsive to previous intramuscular hepatitis B vaccination.Methods:Intradermal recombinant hepatitis B vaccine was administered every second week for a maximum of 4 doses. Hepatitis B surface antibody (anti-HBs) responses were assessed 2 weeks after each dose.Results:Protective anti-HBs levels developed in 17 (94%) of 18 study subjects. Three doses resulted in seroconversion of all responding subjects and the highest geometric mean antibody concentration. The vaccine was well tolerated.Conclusion:More than 90% of previously nonresponsive HCWs responded to intradermal recombinant hepatitis B vaccine with protective anti-HBs levels.

scholarly journals A Study of Persistence of Anti-HBs Antibodies after Vaccination with Recombinant Hepatitis B Vaccine in Healthcare Workers

2018 ◽  
Vol 33 (3) ◽  
pp. 117-122
Author(s):  
Sumio IWASAKI ◽  
Reiko OYAMADA ◽  
Tsubasa WATANABE ◽  
Kiyomi HASUIKE ◽  
Sumito NAKAMURA ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Healthcare Workers ◽  
Hepatitis B Vaccine ◽  
Recombinant Hepatitis

scholarly journals IMMUNOGENICITY OF LOW-DOSE INTRAMUSCULAR AND INTRADERMAL VACCINATION WITH RECOMBINANT HEPATITIS B VACCINE

1997 ◽  
Vol 39 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Marília Dalva TURCHI ◽  
Celina Maria Turchi MARTELLI ◽  
Maria Lúcia FERRAZ ◽  
Antonio Eduardo SILVA ◽  
Divina das Dores de Paula CARDOSO ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Recombinant Dna ◽  
Standard Dose ◽  
Seroconversion Rate ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Antibody Concentration ◽  
Intradermal Vaccination ◽  
Group I ◽  
Significant Difference

The study is a randomized trial using recombinant DNA vaccine to determine whether an intramuscular 10 µg dose or intradermal 2 µg induces satisfactory anti-HBs levels compared to the standard dose of intramuscular 20 µg. participants were 359 healthy medical and nurse students randomly allocated to one of the three groups: Group I - IM 20 µg; Group II - IM 10 µg; Group III - ID 2 µg at 0, 1 and 6 months. Anti-HBs titres were measured after complete vaccine schedule by ELISA/Pasteur. Baseline variables were similar among groups and side effects were mild after any dose. Vaccinees in the IM-10 µg group had seroconversion rate and geometric mean titre (GMT 2344 IU L-1), not significant different from the IM-20 µg group (GMT 4570 IU L-1). On the contrary, 21.4% of the ID - 2 µg recipients mount antibody concentration below 10 IU L1 and GMT of 91 IU L-1, a statiscally significant difference compared with the standard schedule IM-20 µg (p < 0.001). A three dose regimen of half dosse IM could be considered an appropriate schedule to prevent hepatitis B in young health adults which is of relevance to the expansion of hepatitis B vaccine programme

Low Seroconversion with Hepatitis B Vaccination in Peritoneal Dialysis Patients

1996 ◽  
Vol 16 (4) ◽  
pp. 370-373 ◽  
Author(s):  
Abdul N. Khan ◽  
Judy Bernardini ◽  
Raymond M. Rault ◽  
Beth Piraino
Keyword(s):  
Peritoneal Dialysis ◽  
Hepatitis B ◽  
Outcome Measure ◽  
Seroconversion Rate ◽  
Hepatitis B Vaccine ◽  
The Other ◽  
Hepatitis B Vaccination ◽  
Recombinant Hepatitis ◽  
Dialysis Patients ◽  
Main Outcome Measure

Objective To compare seroconversion using hepatitis B vaccine between hemodialysis (HD) and peritoneal dialysis (PD) patients. Design Data on PD patients vaccinated were collected retrospectively for the period 1992 to 1995. The data on HD patients were collected prospectively from 1991 to 1994. Setting A university outpatient dialysis center. Participants All adult patients who received all four doses of hepatitis B vaccine while on dialysis were included (47 PD and 50 HD patients). Intervention Recombinant hepatitis B vaccine (Engerix), 40 μg IM was administered at 0, 1, 2, and 6 months. Main Outcome Measure Seroconversion was measured after completion of the vaccination series. Results 74% of the HD patients seroconverted compared to 53 % of PD patients (p = 0.03). Older, heavier patients compared to all the other patients had a lower seroconversion rate in both the HD patients (55 % vs. 78 %) and PD patients (38 % vs. 59 %) (p = 0.03). Conclusion The seroconversion rate to recombinant hepatitis B vaccine is lower in patients on PD than on HD for unclear reasons. Further studies are required to determine the etiology of this difference.

Comparison of Higher-Dose Intradermal Hepatitis B Vaccination to Standard Intramuscular Vaccination of Healthcare Workers

2000 ◽  
Vol 21 (4) ◽  
pp. 264-269 ◽  
Author(s):  
Elizabeth A. Henderson ◽  
Thomas J. Louie ◽  
Karam Ramotar ◽  
Donna Ledgerwood ◽  
Karen Myrthu Hope ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Geometric Mean ◽  
Cost Effective ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Random Allocation ◽  
Intradermal Vaccination ◽  
B Virus ◽  
Microparticle Enzyme Immunoassay

Objective.To compare the immunogenicity of hepatitis B vaccine administered via intradermal (ID) versus intramuscular (IM) route.Methods:Subjects chose either to specify the route of immunization or to undergo random allocation to vaccination by the ID (0.15 mL) or the IM (1.0 mL) route. Yeast-derived recombinant hepatitis B vaccine was given at 0, 30, and 180 days. Hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb) were measured by microparticle enzyme immunoassay.Results:763 subjects were enrolled. Baseline screening identified 65 subjects (8%) who were positive for HBsAb or HBcAb. Vaccination was completed by 590 (85%) of 698 enrollees (370 ID, 220 IM). Seroconversion rates (geometric mean titers [GMT]>0 IU/mL HBsAb) for those vaccinated ID were 99% and 96% for screening at 9 months and 1 year post-vaccination, respectively; subjects vaccinated intramuscularly had similar rates of 95% and 96%. Seropositivity rates (GMT ≥ 10 IU/mL HBsAb) showed a similar pattern, with 95%, 92%, and 73% at 9 months and 1 and 2 years, respectively, for those vaccinated ID, and 94%, 93%, and 81% for those having IM vaccination. GMT for HBsAb was significantly higher for individuals vaccinated IM than for those vaccinated ID (P<.0001). The GMT ratio for the IM and ID routes decreased over time, being 9.3 at 9 months, 7.8 at 1 year, and 5.9 at 2 years. An unanticipated side effect of intradermal vaccination was skin discoloration at injection sites, which persisted for at least 2 years postvaccination. Two thirds (112/166) of respondents reported that they would have selected the ID route despite the discoloration.Conclusions:Higher-dose ID vaccination (3 vs 1 μg per injection) uses one sixth of the dose required for standard IM vaccination. It is a cost-effective way to vaccinate populations against hepatitis B virus, but the long-term efficacy of the ID route must still be investigated.

scholarly journals Compliance with and response to hepatitis B vaccination in remaining quilombo communities in Central Brazil

2009 ◽  
Vol 25 (4) ◽  
pp. 738-742 ◽  
Author(s):  
Ana Rita C. Motta-Castro ◽  
Selma A. Gomes ◽  
Clara F. T. Yoshida ◽  
Juliana C. Miguel ◽  
Sheila A. Teles ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Geometric Mean ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Hepatitis B Virus Infection ◽  
Education Programs ◽  
Central Brazil ◽  
Vaccination Scheme ◽  
B Virus ◽  
Male Sex

Compliance with and responses to the hepatitis B vaccine were evaluated in remaining quilombo communities in Central Brazil. A total of 708 individuals who were susceptible to hepatitis B virus infection were invited to participate in the hepatitis B vaccination program in eight communities. Although 567 (80%) individuals received the first dose, only 198 (28%) complied with the full vaccination scheme. Of 148 subjects who agreed to be tested for anti-HBs, 123 (83.1%; 95%CI: 75.9-88.6) responded to the vaccine. A geometric mean titer of 512mIU/mL (95%CI: 342.5-765.3) was found. Male sex and older age were independently associated with non-response. Additional health education programs and alternative hepatitis B vaccine schedules are needed to improve the vaccination coverage in these communities in Central Brazil.

Gluten Intake Interferes With the Humoral Immune Response to Recombinant Hepatitis B Vaccine in Patients With Celiac Disease

PEDIATRICS ◽  
2008 ◽  
Vol 121 (6) ◽  
pp. e1570-e1576 ◽  
Author(s):  
E. Nemes ◽  
E. Lefler ◽  
L. Szegedi ◽  
A. Kapitany ◽  
J. B. Kovacs ◽  
...  
Keyword(s):  
Immune Response ◽  
Celiac Disease ◽  
Hepatitis B ◽  
Humoral Immune Response ◽  
Hepatitis B Vaccine ◽  
Recombinant Hepatitis ◽  
Humoral Immune

scholarly journals Hepatitis B vaccine knowledge and self-reported vaccination status among healthcare workers in a conflict region in northeastern Nigeria

2020 ◽  
Vol 8 ◽  
pp. 251513551990074 ◽  
Author(s):  
Farouq Muhammad Dayyab ◽  
Garba Iliyasu ◽  
Bashir Garba Ahmad ◽  
Abdulaziz Tijjani Bako ◽  
Sepu Saraya Ngamariju ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Healthcare Workers ◽  
Medical Center ◽  
Primary Objective ◽  
Vaccination Status ◽  
Hepatitis B Vaccine ◽  
Good Knowledge ◽  
Hepatitis B Vaccination ◽  
Cross Sectional ◽  
Tertiary Referral Center

Background Hepatitis B virus (HBV) infection is highly endemic in Nigeria. The primary objective of this study is to describe the knowledge, self-reported vaccination status, and intention of healthcare workers to receive hepatitis B vaccine at a tertiary referral center in conflict-ravaged northeastern Nigeria. Methods This was cross-sectional analytical study among medical practitioners, nurses, laboratory workers, health attendants, pharmacists, and radiographers working at Federal Medical Center Nguru, Yobe State. Written informed consent was obtained from all study participants. Data were obtained using questionnaires and entered into a Microsoft Excel spreadsheet, cleaned and analyzed using JMP Pro software. Results Of the 182 participants, we found that 151 (82.97%), 81 (44.51%), 85 (46.70%), and 33 (18.13%) had good knowledge of HBV, good knowledge of hepatitis B vaccine, were vaccinated against HBV by the least dose, and had a complete hepatitis B vaccination status, respectively. The lack of availability of the vaccine was the main reason for not receiving the vaccine among the unvaccinated 36/91 (39.56%), followed by not knowing where to access the vaccine 19/91 (20.88%). Conclusion The study highlights the need for strategies to ensure the availability of hepatitis B vaccine in conflict settings and need for vaccinology training given the suboptimal level of awareness and uptake of the hepatitis B vaccine among the healthcare workers.

Sign in / Sign up

Export Citation Format

Share Document